NVAX Novavax
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. In June 2013, Novavax acquired the Matrix-M adjuvant platform with the purchase of Swedish company Isconova AB and renamed its new subsidiary Novavax AB.
Company profile
Ticker
NVAX
Exchange
Website
CEO
Stanley Erck
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
SEC CIK
Corporate docs
IRS number
222816046
NVAX stock data
()
News
Novavax Announces Leadership Updates; Says CFO Stepping Down
13 Apr 21
12 Health Care Stocks Moving In Tuesday's Intraday Session
13 Apr 21
34 Stocks Moving In Tuesday's Mid-Day Session
13 Apr 21
Why Novavax Stock Is Popping, Despite Vaccine Rollout Issues: Report
13 Apr 21
Why Vaccine Stocks Pfizer, BioNTech, Moderna And Novavax Are Higher
13 Apr 21
Press releases
Novavax Announces Leadership Updates
13 Apr 21
Novavax Announces Leadership Updates
13 Apr 21
Thinking about trading options or stock in Zai Lab, Novavax, Johnson & Johnson, Marathon Digital, or Riot Blockchain?
13 Apr 21
Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
8 Apr 21
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
5 Apr 21
Calendar
28 Feb 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Novavax earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 648.74M | 648.74M | 648.74M | 648.74M | 648.74M | 648.74M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 60.95M | 34.73M | 42.86M | 3.55M |
| Cash used (since last report) | n/a | n/a | 210.63M | 120.01M | 148.1M | 12.25M |
| Cash remaining | n/a | n/a | 438.11M | 528.73M | 500.64M | 636.49M |
| Runway (months of cash) | n/a | n/a | 7.2 | 15.2 | 11.7 | 179.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Apr 21 | Trizzino John | Common Stock | Sell | Dispose S | No | Yes | 178.03 | 191 | 34K | 287 |
| 5 Apr 21 | Trizzino John | Common Stock | Payment of exercise | Dispose F | No | No | 177.29 | 179 | 31.73K | 478 |
| 5 Apr 21 | Trizzino John | Common Stock | Sale back to company | Dispose D | No | No | 177.29 | 13 | 2.3K | 657 |
| 5 Apr 21 | Trizzino John | Common Stock | Option exercise | Aquire M | No | No | 177.29 | 383 | 67.9K | 670 |
| 5 Apr 21 | Trizzino John | Common Stock | Sell | Dispose S | No | Yes | 190.1 | 3,021 | 574.29K | 287 |
| 5 Apr 21 | Trizzino John | Common Stock | Option exercise | Aquire M | No | Yes | 5.95 | 2,083 | 12.39K | 3,308 |
| 5 Apr 21 | Trizzino John | Common Stock | Option exercise | Aquire M | No | Yes | 46 | 521 | 23.97K | 1,225 |
| 5 Apr 21 | Trizzino John | Common Stock | Option exercise | Aquire M | No | Yes | 27.6 | 417 | 11.51K | 704 |
| 5 Apr 21 | Trizzino John | Stock Appreciation Right Common Stock | Option exercise | Dispose M | No | No | 5.95 | 383 | 2.28K | 11,501 |
| 5 Apr 21 | Trizzino John | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 5.95 | 2,083 | 12.39K | 62,501 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
52.7% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 347 |
| Opened positions | 98 |
| Closed positions | 53 |
| Increased positions | 114 |
| Reduced positions | 83 |
13F shares |
Current |
|---|---|
| Total value | 4.71B |
| Total shares | 38.89M |
| Total puts | 4.89M |
| Total calls | 3.35M |
| Total put/call ratio | 1.5 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 5.6M | $624.32M |
| BLK Blackrock | 5.13M | $571.57M |
| Ra Capital Management | 3.79M | $422.46M |
| FMR | 1.75M | $195.21M |
| STT State Street | 1.73M | $192.49M |
| BEN Franklin Resources | 1.28M | $142.54M |
| Susquehanna International | 1.24M | $138.27M |
| Capital World Investors | 1.19M | $132.22M |
| Perceptive Advisors | 1.04M | $116.31M |
| Geode Capital Management | 958.31K | $106.86M |
Financial report summary
?Competition
Geovax Labs • Mymetics • Dynavax Technologies • Inovio Pharmaceuticals • Altimmune • Tonix Pharmaceuticals Holding • Selecta Biosciences • Vir BiotechnologyRisks
- We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.
- Because we depend on third-parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.
Management Discussion
- For our discussion of the year ended December 31, 2019, compared to the year ended December 31, 2018, please read Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations located in Annual Report on Form 10-K for the year ended December 31, 2019.
- Revenue for 2020 was $475.6 million as compared to $18.7 million for 2019, an increase of $460.6 million. The significant increase in revenue in 2020 was a result of our development activities related to NVX-CoV2373 and was primarily comprised of revenue for services performed under the OWS Agreement and the CEPI Funding Agreement. Revenue for the year ended December 31, 2019 was primarily comprised of revenue for services performed under the BMGF Grant Agreement and recovery of costs on the close-out of our contract with HHS BARDA.
- We expect revenue in 2021 to significantly increase due to our NVX-CoV2373 program, which we anticipate will continue to be funded by OWS and CEPI and/or other revenue sources. Further, we anticipate bringing our NVXCoV2373 vaccine candidate to market following global regulatory approvals which, if achieved, should significantly impact revenue (also see below under Liquidity and Capital Resources in this Management's Discussion and Analysis). In anticipation, we have entered into various APAs with government customers that are expected to result in the delivery of approximately 200 million doses of NVX-CoV2373 throughout 2021 and into the first half of 2022. We also entered into multiple supply and license agreements with strategic partners to supply NVX-CoV2373 in their specified territories under which we are entitled to receive royalty revenue from the sale of NVX-CoV2373 by such partners.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accommodate, accrual, advice, African, AGC, Aid, allegedly, Alliance, allotted, alter, altogether, Alton, American, APA, APC, appraisal, arena, Asian, ATI, Australian, automated, automatic, Azar, back, ballot, bar, bark, begun, bench, Billingham, Bilt, Bilthoven, Biosafety, bioscience, bivalent, blinded, Bohumil, bold, bona, boost, boosting, bribery, Britain, Buyer, California, Canadian, cancer, Carolina, CBRN, CCPA, CDMO, cell, Centre, certified, certiorari, cholesterol, Circuit, client, CMO, CMS, coaching, coincide, commensurate, comment, Commissioner, Commonwealth, composed, concealing, concierge, configuration, Congressional, Consortium, constrain, constraint, consummated, convalescent, convenience, convenient, convicted, Council, countermeasure, COVAX, Covino, CPRA, Creation, creativity, CRO, crossover, culture, customary, Cut, cybersecurity, CZ, Czech, database, David, de, debarment, degradation, DEI, delegated, delete, demographic, devise, diagnose, disaster, discretion, distancing, District, DoD, drop, EAC, embezzling, encoding, endeavoring, Energy, England, entirety, environment, equitable, escape, EUA, evidencing, evolution, exact, expedient, expenditure, explicitly, explore, exploring, falsifying, FCA, FCPA, FDB, fide, fill, filling, folded, forefront, forgivable, forma, formulary, fortunate, frequency, frugiperda, FUJIFILM, fused, gave, Gavi, geolocation, goal, grandfathered, grantor, Great, Gregg, GSK, guarantor, halt, harbor, harmonized, Hatch, heading, heard, heavily, HITECH, illustrated, imaging, imbued, IMM, implicitly, inactivated, injection, injunction, injured, Inovio, input, inserted, inseverable, interdependent, interrelated, iPDP, Ireland, irregularity, irreversible, Johnson, joined, joining, jointly, Judge, judgment, knowledge, Korea, Korean, Koruna, Labour, landscape, LatinX, Learning, led, legitimate, lessee, lessor, leverage, leveraging, library, linked, LinkedIn, loan, lowest, LV, lymph, Majesty, managerial, Margaret, mask, Matter, McGlynn, meaningfully, mechanism, Medsafe, Member, Memorandum, memory, met, Mexico, MHRA, Minister, Ministry, misconduct, moderate, modification, Molina, month, Montreal, Mott, MOU, mutual, nanometer, nationwide, necessitate, necessity, negligence, network, networking, noncash, nonclinical, noncompliance, North, Northern, notify, Nuclear, numerically, nurse, nurture, NVX, occupy, offense, official, online, onset, onsite, opt, optimistic, oral, outbreak, outpatient, output, outsized, overcome, pace, paired, Park, partnership, paused, perception, phospholipid, physician, placement, platform, play, PMDA, polyfunctional, Polypeptide, Poonawalla, Portability, posted, power, Praha, precise, preclude, predetermined, predominant, preliminarily, PREP, prepay, principle, pro, problem, procured, procurement, proud, punishable, Queen, RA, Radiological, randomly, reaction, reactogenicity, reallocate, Rebate, recall, receptor, recoup, refund, relief, relocated, remanded, remeasure, remote, remotely, Removal, remove, renovation, reproduction, Republic, reschedule, revocation, role, royalty, sabotage, safer, saponin, screening, sera, Serial, seropositive, SIIPL, Similarly, Sinopharm, Sinovac, SK, slated, social, solidify, solving, South, speculation, Spodoptera, standalone, stay, stealing, stemming, stockpile, strict, subcontractor, subpopulation, Subscription, substantive, sued, SUKL, supplier, Supreme, Switzerland, Takeda, talent, Taskforce, Taxpayer, TCJA, teaching, team, technique, temperature, temporal, terrorism, TGA, therapy, thought, tiered, timeline, today, tracker, travel, treasury, trend, tuition, unblinded, unconstitutional, Undefinitized, uneven, unexpected, unfair, unfunded, unilaterally, unmanaged, unprecedented, unprofitable, unrecoverable, unrest, unsatisfied, unsuitable, unusual, urgent, vacation, variant, video, voluntary, war, Warp, water, Waxman, weather, welfare, whistleblower, willfully, Zealand
Removed:
Ablynx, accumulation, activation, adjusted, allergic, amplitude, anniversary, arbitrary, awardee, bacteria, Bavarian, bid, Bipartisan, Carlo, carried, cellular, cheaper, climate, Clopper, comparability, confirmatory, conformation, correlation, CPLB, curb, cure, cytotoxic, Datamonitor, delist, delisted, delisting, device, difficulty, diluting, disposable, Dr, enactment, excellent, expiring, exploratory, feasible, Frech, GE, GEHC, generating, hampered, hemagglutination, hidden, immunological, immunologically, immunostimulatory, Immunovaccine, inhibition, innate, leasing, listing, Mab, maximizing, monoclonal, Monte, NIAID, nominal, Nordic, originally, participating, particle, pathogen, physical, poorly, prequalification, preservation, preterm, prioritize, projection, prolong, QUALITATIVE, qualitatively, recoverability, recurring, regulator, repeating, replication, retained, revised, risen, Rock, Sarah, season, seasoned, simulation, spouse, stimulate, structure, SUPPLEMENTARY, synthetic, transition, undiscounted, Vaxart, win, Wyeth
Financial reports
10-K
2020 FY
Annual report
28 Feb 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
NT 10-Q
Notice of late quarterly filing
10 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
Current reports
8-K
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
2 Mar 21
8-K
Entry into a Material Definitive Agreement
19 Feb 21
8-K
Entry into a Material Definitive Agreement
22 Jan 21
8-K
Regulation FD Disclosure
11 Jan 21
8-K
Entry into a Material Definitive Agreement
7 Jan 21
8-K/A
Departure of Directors or Certain Officers
16 Dec 20
8-K
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
9 Dec 20
8-K
Novavax Reports Third Quarter 2020 Financial and Operational Results
10 Nov 20
8-K
Other Events
10 Nov 20
8-K
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
3 Nov 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Jan 21
424B5
Prospectus supplement for primary offering
10 Nov 20
424B5
Prospectus supplement for primary offering
10 Nov 20
424B7
Prospectus with selling stockholder info
10 Aug 20
S-8
Registration of securities for employees
10 Aug 20
424B5
Prospectus supplement for primary offering
18 May 20
S-3ASR
Automatic shelf registration
11 Mar 20
424B5
Prospectus supplement for primary offering
2 Mar 20
424B5
Prospectus supplement for primary offering
21 Jan 20
S-3
Shelf registration
31 Dec 19
Proxies
DEFA14A
Additional proxy soliciting materials
18 Jun 20
DEFA14A
Additional proxy soliciting materials
12 May 20
DEF 14A
Definitive proxy
12 May 20
DEFA14A
Additional proxy soliciting materials
16 May 19
DEF 14A
Definitive proxy
16 May 19
DEF 14A
Definitive proxy
1 Apr 19
PRE 14A
Preliminary proxy
21 Mar 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
Other
EFFECT
Notice of effectiveness
10 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
UPLOAD
Letter from SEC
5 Jan 20
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
11 Jun 18
EFFECT
Notice of effectiveness
11 Jan 18
CORRESP
Correspondence with SEC
9 Jan 18
UPLOAD
Letter from SEC
8 Jan 18
UPLOAD
Letter from SEC
20 Dec 17
CORRESP
Correspondence with SEC
3 Dec 17
Ownership
4
NOVAVAX / John Trizzino ownership change
7 Apr 21
4
NOVAVAX / John A Herrmann III ownership change
30 Mar 21
4
NOVAVAX / JAMES F YOUNG ownership change
25 Mar 21
4
NOVAVAX / MICHAEL A MCMANUS JR ownership change
23 Mar 21
4
NOVAVAX / GARY C EVANS ownership change
17 Mar 21
4
NOVAVAX / Gregory M Glenn ownership change
17 Mar 21
4
NOVAVAX / John Trizzino ownership change
9 Mar 21
4
NOVAVAX / John A Herrmann III ownership change
2 Mar 21
4
NOVAVAX / Gregory M Glenn ownership change
18 Feb 21
4
NOVAVAX / Gregory M Glenn ownership change
18 Feb 21
Patents
GRANT
Utility
Coronavirus vaccine formulations
23 Mar 21
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
APP
Utility
Quil a Fraction with Low Toxicity and Use Thereof
4 Nov 20
Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens.
GRANT
Utility
Composition comprising iscom particles and live micro-organisms
26 Oct 20
Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules.
APP
Utility
CorrectedComposition Comprising Iscom Particles and Live Micro-organisms
14 Oct 20
Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules.
GRANT
Utility
Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
24 Aug 20
Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions.
Transcripts
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
9 Nov 20
2020 Q2
Earnings call transcript
10 Aug 20
2020 Q1
Earnings call transcript
11 May 20
2019 Q4
Earnings call transcript
11 Mar 20
2019 Q3
Earnings call transcript
7 Nov 19
2019 Q2
Earnings call transcript
10 Aug 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
18 Mar 19
2018 Q3
Earnings call transcript
7 Nov 18
Reddit threads
$ATOS - Currently trading 45% under recent Direct Offering from $2.88 to $1.75
13 Apr 21
Morning Update for Tuesday, 04/13/21
13 Apr 21
J&J vaccine recommended to be paused in the US. Get ready for the discounts - gonna be a wild ride! 😬
13 Apr 21
Have you ever lost so much money on a particular stock that you just refused to sell it out of principle?
12 Apr 21
What Are Your Moves Tomorrow, April 12, 2021
11 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - April 11, 2021
10 Apr 21
$NVAX: Extremely Coiled and Right At The Very End of Pennant; Likely Major Breakout Above or Below Imminent Next Week. ///Relevant Tags: $SPX $SPY $QQQ $IBB $MRNA $PFE $GSK \\\
10 Apr 21
What do you consider to be your most undervalued stock in your portfolio?
9 Apr 21
$PDSB Low floater shares are scarce 40%+ locked up by institutions & insiders. 22 million shares outstanding.
7 Apr 21
$PDSB Fortune to made here!!!
7 Apr 21